Article Text

Download PDFPDF
Immunotherapy in endometrial cancer
  1. Haider Mahdi1,
  2. Anca Chelariu-Raicu2 and
  3. Brian M Slomovitz3
  1. 1 Division of Gynecologic Oncology, UPMC Magee Womens Hospital, Pittsburgh, Pennsylvania, USA
  2. 2 LMU University Hospitals Munich Department of Infections and Tropical Medicine, Munchen, Germany
  3. 3 Gynecologic Oncology, Mount Sinai Medical Center, Miami Beach, Florida, USA
  1. Correspondence to Dr Brian M Slomovitz, Gynecologic Oncology, Mount Sinai Medical Center, Miami Beach, FL 33140, USA; bslomo{at}


The Cancer Genome Atlas (TCGA) endometrial cancer data expanded our knowledge about the role of different immunotherapeutic approaches based on molecular subtypes. Immune checkpoint inhibitors demonstrated distinct antitumor activities as monotherapy or in combination. In microsatellite unstable (microsatellite instability-high) endometrial cancer, immunotherapy with immune checkpoint inhibitors showed promising single agent activity in recurrent settings. Different strategies are needed to enhance the response or reverse resistance to immune checkpoint inhibitors, or both, in microsatellite instability-high endometrial cancer. On the other hand, single immune checkpoint inhibitors showed underwhelming efficacy in microsatellite stable endometrial cancer but this was significantly improved using a combination approach. Furthermore, studies are also needed to improve response along with ensuring safety and tolerability in microsatellite stable endometrial cancer. This review summarizes the current indications of immunotherapy for the treatment of advanced and recurrent endometrial cancer. We also outline potential future strategies for an immunotherapy based combination approach in endometrial cancer to combat resistance or enhance response to immune checkpoint inhibitors, or both.

  • Endometrial Neoplasms

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @gyncancermd

  • Contributors All authors contributed equally in writing and reviewing the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.